LCAR-M23 / Legend Biotech - LARVOL DELTA

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer (clinicaltrials.gov) - P1 | N=15 | Terminated | Sponsor: Shanghai East Hospital | N=34 ➔ 15 | Trial completion date: Nov 2024 ➔ Jun 2022 | Recruiting ➔ Terminated | Trial primary completion date: Nov 2022 ➔ Jun 2022; Both the sponsors and collaborator are considering terminating the study.

CAR T-Cell Therapy • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor • MSLN

A Single-Center, Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer (clinicaltrials.gov) - P1; N=34; Recruiting; Sponsor: Shanghai East Hospital; Not yet recruiting ➔ Recruiting

CAR T-Cell Therapy • Clinical • Enrollment open • Oncology • Ovarian Cancer • Solid Tumor

A Single-Center, Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer (clinicaltrials.gov) - P1; N=34; Not yet recruiting; Sponsor: Shanghai East Hospital

CAR T-Cell Therapy • Clinical • New P1 trial • Oncology • Ovarian Cancer • Solid Tumor